Correction to: Drugs (2021) 81:587–594 10.1007/s40265-021-01481-6
Page 3, Table 2, ‘Complete TMA response’ section:
Table 2.
Efficacy of ravulizumab in treatment-naïve patients with atypical haemolytic uremic syndrome in clinical studies
| Outcomes | Adults (n = 56) [19] | Paediatric pts (n = 18) [13, 21] |
|---|---|---|
| Complete TMA responsea (% pts) [95% CI] | 53.6 [39.6–67.5] | 77.8 [52.4–93.6] |
| Platelet count ≥ 150 × 109/Lb (% pts) [95% CI] | 83.9 [73.4–94.4] | 94.4 [72.7–99.9] |
| Lactate dehydrogenase ≤ 246 U/Lb (% pts) [95% CI] | 76.8 [64.8–88.7] | 88.9 [65.3–98.6] |
| Serum creatinine ≥ 25% improvement from BLb (% pts) [95% CI] | 58.9 [45.2–72.7] | 83.3 [58.6–96.4] |
| Haematologic normalizationc (% pts) [95% CI] | 73.2 [60.7–85.7] | 88.9 [NA] |
| Haemoglobin ≥ 20 g/L (% pts) [95% CI] | 71.4 [58.8–84.2] | 88.9 [65.3–98.6] |
| Median changes from BL at day 183 (BL) | ||
| Platelet count (× 109/L) ↑ | 125.0 (95.3) | 247.0 (51.3) |
| Lactate dehydrogenase (U/L) ↓ | 310.8 (508) | 1851.5 (1963.0) |
| Estimated glomerular filtration rate (mL/min/1.73 m2) ↑ | 29.0 (10) | 80.0 (22.0) |
| Haemoglobin (g/L) ↑ | 35.0 (85) | NA (74.3) |
BL baseline, NA not available, pts patients, TMA thrombotic microangiopathy, ↑ increased, ↓ decrease
aPrimary endpoint, assessed through week 26; patients had to meet criteria for all TMA components concurrently, and each criterion had to be met at two separate assessments obtained ≥ 28 days apart and at any measurement in between
bComponent of complete TMA response
cPlatelet count ≥ 150 × 109/L plus lactate dehydrogenase ≤ 246 U/L
“Serum creatinine ≥ 25% ↑ from BLb (% pts) [95% CI]”
Should read:
“Serum creatinine ≥ 25% improvement from BLb (% pts) [95% CI]”
Page 3, Table 2, foot note ‘b’:
“bComponent of complete TAM response”
Should read:
“bComponent of complete TMA response”
The corrected Table 2 is as follows: